Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities of continuing operations:
Net income (loss)	$ (3,636,201)	$ (3,582,029)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	664,771	611,650
Amortization of debt discount	417,198	325,619
Common stock issued for financing costs	32,418	2,250
Common stock issued in exchange for fees and services	606,797	330,250
Deferred taxes	(26,752)	(6,175)
Derivative expense	42,140	0
Stock-based compensation	48,600	294,743
Loss on extinguishment of debt	363,468	0
Unrealized (gain) loss on change in fair value of derivative liabilities	13,473	0
Changes in operating assets and liabilities:
Accounts receivable	57,376	(64,853)
Inventory	(21,481)	(120,512)
Prepaid expenses and other current assets	8,594	501,811
Operating lease right of use assets	16,802	0
Other assets	33,745	8,911
Accounts payable	434,854	565,678
Accrued liabilities	266,809	311,492
Advanced payments and deferred revenues	(1,445)	290,174
Income taxes payable and other noncurrent liabilities	(35,118)	(43,033)
Related party payables	(409,095)	(242,611)
Net cash provided by (used in) operating activities	(1,123,047)	(816,635)
Cash flows from investing activities:
Purchase of fixed assets	(284,629)	(700,493)
Net cash provided by (used in) investing activities	(284,629)	(700,493)
Cash flows from financing activities:
Proceeds from issuance of preferred stock, net of issuance costs	411,151	0
Proceeds from issuance of common stock, net of issuance costs	1,008,849	76,218
Proceeds from exercise of common stock purchase warrants, net of issuance costs	0	61,500
Proceeds from issuance of convertible debentures	95,000	1,496,389
Proceeds from issuance of senior, secured promissory notes	0	80,000
Repayments of convertible debentures	(184,000)	(75,000)
Net cash provided by (used in) financing activities	1,331,000	1,639,107
Effect of exchange rates on cash and cash equivalents	25,680	(156,266)
Net increase (decrease) in cash and cash equivalents	(50,996)	(34,287)
Cash and cash equivalents at beginning of period	633,593	436,869
Cash and cash equivalents at end of period	582,597	402,582
Supplemental disclosure of cash flow information:
Cash paid for interest	521,408	70,253
Cash paid for income taxes	0	0
Supplemental disclosure of non-cash investing and financing activities:
Common stock issued related to acquisition of business	0	52,500
Common stock issued for financing costs incurred in connection with convertible and promissory notes	0	744,179
Common stock issued in connection with long term service contracts	0	72,000
Common stock issued to reduce convertible and promissory notes payable	0	671,376
Common stock issued to reduce accounts payable and other accrued liabilities	389,440	0
Discount for beneficial conversion features on convertible debentures	51,730	801
Discount related to fair value of derivative liabilities associated with convertible debentures	$ 43,270	$ 0